Phagocytic function

Phagocytic function refers to the physiological process by which specialized immune cells, known as professional phagocytes (including macrophages, neutrophils, and dendritic cells), identify, engulf, and degrade large particles such as pathogens, apoptotic cells, and cellular debris [1, 9, 11]. This mechanism is fundamental to innate immunity, providing a primary defense against infection and playing a central role in tissue homeostasis and the resolution of inflammation [4, 7, 9]. In oncology, the modulation of phagocytic function is a major area of research, as tumor cells often exploit "don't eat-me" signaling pathways, such as the CD47-SIRPα axis, to evade destruction by tumor-associated macrophages [3, 13]. Conversely, impaired efferocytosis (the phagocytic clearance of apoptotic cells) is associated with chronic inflammatory conditions and autoimmune diseases, where the accumulation of necrotic material triggers maladaptive immune responses [6]. Pharmacological agents such as magrolimab and rituximab target specific surface proteins to either block inhibitory signals or provide pro-phagocytic opsonization, thereby enhancing the clearance of malignant or infected cells [3, 13, 15]. However, therapeutic enhancement of phagocytic function can lead to significant safety concerns, including off-target effects like anemia or neutropenia when self-cells are inadvertently targeted [5, 13]. Additionally, in the central nervous system, excessive microglial phagocytosis can lead to pathological synapse pruning, which is a therapeutic challenge in neurodegenerative diseases [7, 8].

Other names

PhagocytosisEfferocytosisCellular engulfmentPhagocytic activityCellular ingestion

Drugs modulate phagocytic function by interfering with the balance of "eat-me" and "don't eat-me" signals. This includes the use of monoclonal antibodies to block inhibitory receptors (e.g., the CD47-SIRPα axis), agonists to activate pattern recognition receptors (e.g., TLRs), or opsonizing agents that facilitate Fc-receptor-mediated engulfment (ADCP). These interventions aim to either stimulate the removal of pathogenic or malignant cells or suppress excessive phagocytic activity in autoimmune and neurodegenerative contexts [1, 3, 13].